Why Q Care Plus is blending PrEP, birth control, and sexual health in one telehealth platform
Q Care Plus adds ED, hair loss, and birth control services to its virtual platform. Find out how this reshapes stigma-free access to sexual wellness care.
Aidoc secures FDA clearance for first AI triage system covering 14 acute conditions in CT
Aidoc’s CARE AI gets FDA clearance for 14-condition CT triage. Find out how it may reshape emergency imaging, hospital workflows, and clinical AI governance.
Is Zepto Life Technology redefining fungal diagnostics with cell-free DNA technology?
Zepto Life Technology’s FungiFlex Mold Panel enables fast, noninvasive fungal diagnostics from blood. Find out what this could mean for patient care.
Why ProRx’s needle-free TRT could reshape hormone therapy for med spas and DTC providers
ProRx Pharma launches oral testosterone for virtual care delivery. Find out what this means for telehealth TRT models and compounder-led hormone therapy.
BioStem acquires Neox and Clarix as BioTissue refocuses on eye care therapies
BioTissue exits surgical wound care to refocus on eye care innovation, selling Neox and Clarix lines to BioStem. Find out what this deal changes in MedTech.
Is this the end of EMFACE lookalikes? Inside BTL’s cross-border IP enforcement playbook
BTL’s EMFACE wins global IP battle against WonderFace. Find out how this reshapes the energy-based facial therapy market in 2026.
Can EpiSwitch PSE become more than a diagnostic tool in prostate disease management?
Doctors Studio’s ozone pilot shows promising 30-day shifts in prostate biomarkers tracked via EpiSwitch PSE. Could this reshape trial design? Find out.
What the Trinity Tube reveals about the future of multifunctional devices in NICU care
Can a feeding tube that monitors vitals change neonatal care? See why Neotech is backing this multifunctional device startup.
Why FDA’s clearance of ACON’s Flowflex Plus test marks a turning point in home diagnostics
FDA clears Flowflex Plus 4-in-1 test for RSV, flu, and COVID in infants and adults. Find out what this means for diagnostics, families, and industry players.
Is Myriad setting a new performance and pricing benchmark in bioscaffold trauma use?
Can Aroa’s bioscaffold platform reshape trauma care economics? See what Myriad’s MASTRR data means for hospitals, surgeons, and reimbursement.